PTCT:NASDAQ
PTC Therapeutics, Inc.
US$ ६५.०३
arrow_downward
-०.६३%(-०.४१) 1D
US$ ६४.९९
arrow_downward
-०.०६% (-०.०४०)todayPre-market
Closed: नोभेम्बर ९, १६:००:०० GMT-५ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PTCT...
Open
US$ ६६.९०
High
US$ ६६.९०
Low
US$ ६४.१२
Mkt. cap
५.४३ अरब
Avg. vol.
११.७१ लाख
Volume
७७०.००
52-wk high
US$ ९०.८६
52-wk low
US$ ५८.८०
EPS
-US$ १.३८
Beta
०.५२
Shares outstanding
८.३५ करोड
No. of employees
९९१
Open
US$ ६६.९०
High
US$ ६६.९०
Low
US$ ६४.१२
Mkt. cap
५.४३ अरब
Avg. vol.
११.७१ लाख
Volume
७७०.००
52-wk high
US$ ९०.८६
52-wk low
US$ ५८.८०
EPS
-US$ १.३८
Beta
०.५२
Shares outstanding
८.३५ करोड
No. of employees
९९१
News stories
From web sources and news partners
Yahoo! Finance Canada
·
३ दिन पहिले
PTC Therapeutics, Inc. (PTCT) Seasonal Returns Chart - Yahoo Finance
Profile
PTC Therapeutics, Inc. is an U.S.-based pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapies that alter gene expression via post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees९९१
Founded१९९८ जनवरी १
HeadquartersWarren, न्यु जर्सी, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Websiteptcbio.com